Literature DB >> 19869998

THE ACTION OF A SPECIFIC ENZYME UPON THE DERMAL INFECTION OF RABBITS WITH TYPE III PNEUMOCOCCUS.

K Goodner1, R Dubos, O T Avery.   

Abstract

The action of the enzyme which specifically decomposes the capsular polysaccharide of Type III Pneumococcus has been tested in Type III pneumococcus dermal infections in rabbits. When injected in sufficient amounts, this enzyme is capable of bringing about a favorable and early termination of the experimental disease which ordinarily is fatal in nearly all instances. The results of the present study yield further evidence that the capsular substance is of great importance in pneumococcus infection, since, in so far as known, the only action of which the specific enzyme is capable is that of decomposing the capsular polysaccharide.

Entities:  

Year:  1932        PMID: 19869998      PMCID: PMC2132114          DOI: 10.1084/jem.55.3.393

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  THE SPECIFIC ACTION OF A BACTERIAL ENZYME ON PNEUMOCOCCI OF TYPE III.

Authors:  O T Avery; R Dubos
Journal:  Science       Date:  1930-08-08       Impact factor: 47.728

2.  STUDIES ON IMMUNITY TO PNEUMOCOCCUS MUCOSUS (TYPE III) : II. THE INFECTIVITY OF TYPE III PNEUMOCOCCUS FOR RABBITS.

Authors:  W S Tillett
Journal:  J Exp Med       Date:  1927-05-31       Impact factor: 14.307

3.  EXPERIMENTAL INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS.

Authors:  K Goodner
Journal:  J Exp Med       Date:  1928-06-30       Impact factor: 14.307

4.  FURTHER EXPERIMENTS WITH THE INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS.

Authors:  K Goodner
Journal:  J Exp Med       Date:  1928-08-31       Impact factor: 14.307

5.  THE PRODUCTION OF INFECTION WITH PNEUMOCOCCI IN RABBITS BY INTRADERMAL INOCULATION OF TYPE III PNEUMOCOCCI, THE TREATMENT WITH SPECIFIC ANTISERUM, AND A COMPARISON WITH TYPE I INFECTIONS.

Authors:  E L Watson; G Cooper
Journal:  J Exp Med       Date:  1930-11-30       Impact factor: 14.307

6.  THE PATHOLOGY OF EXPERIMENTAL DERMAL PNEUMOCOCCUS INFECTION IN THE RABBIT.

Authors:  C P Rhoads; K Goodner
Journal:  J Exp Med       Date:  1931-06-30       Impact factor: 14.307

7.  THE DEVELOPMENT AND LOCALIZATION OF THE DERMAL PNEUMOCOCCIC LESION IN THE RABBIT.

Authors:  K Goodner
Journal:  J Exp Med       Date:  1931-11-30       Impact factor: 14.307

8.  FACTORS AFFECTING THE YIELD OF SPECIFIC ENZYME IN CULTURES OF THE BACILLUS DECOMPOSING THE CAPSULAR POLYSACCHARIDE OF TYPE III PNEUMOCOCCUS.

Authors:  R Dubos
Journal:  J Exp Med       Date:  1932-02-29       Impact factor: 14.307

  8 in total
  11 in total

1.  Parenteral Administration of Capsule Depolymerase EnvD Prevents Lethal Inhalation Anthrax Infection.

Authors:  David Negus; Julia Vipond; Graham J Hatch; Emma L Rayner; Peter W Taylor
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

2.  Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1.

Authors:  Andrea Zelmer; Melissa J Martin; Ozan Gundogdu; George Birchenough; Rebecca Lever; Brendan W Wren; J Paul Luzio; Peter W Taylor
Journal:  Microbiology (Reading)       Date:  2010-04-15       Impact factor: 2.777

Review 3.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

4.  The T7-related Pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties.

Authors:  Anneleen Cornelissen; Pieter-Jan Ceyssens; Jeroen T'Syen; Helena Van Praet; Jean-Paul Noben; Olga V Shaburova; Victor N Krylov; Guido Volckaert; Rob Lavigne
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

5.  Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype.

Authors:  Naseem Mushtaq; Maria B Redpath; J Paul Luzio; Peter W Taylor
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

6.  EXPERIMENTAL TYPE III PNEUMOCOCCUS PNEUMONIA IN MONKEYS : I. PRODUCTION AND CLINICAL COURSE.

Authors:  T Francis; E E Terrell
Journal:  J Exp Med       Date:  1934-04-30       Impact factor: 14.307

7.  EXPERIMENTAL TYPE III PNEUMOCOCCUS PNEUMONIA IN MONKEYS : II. TREATMENT WITH AN ENZYME WHICH DECOMPOSES THE SPECIFIC CAPSULAR POLYSACCHARIDE OF PNEUMOCOCCUS TYPE III.

Authors:  T Francis; E E Terrell; R Dubos; O T Avery
Journal:  J Exp Med       Date:  1934-04-30       Impact factor: 14.307

8.  STUDIES ON THE QUANTITATIVE ACTION OF A SPECIFIC ENZYME IN TYPE III PNEUMOCOCCUS DERMAL INFECTION IN RABBITS.

Authors:  K Goodner; R Dubos
Journal:  J Exp Med       Date:  1932-09-30       Impact factor: 14.307

9.  THE EVALUATION OF ACTIVE RESISTANCE TO PNEUMOCOCCUS INFECTION IN RABBITS.

Authors:  K Goodner; E G Stillman
Journal:  J Exp Med       Date:  1933-07-31       Impact factor: 14.307

10.  Characterisation of Bacteriophage-Encoded Depolymerases Selective for Key Klebsiella pneumoniae Capsular Exopolysaccharides.

Authors:  George Blundell-Hunter; Mark C Enright; David Negus; Matthew J Dorman; Gemma E Beecham; Derek J Pickard; Phitchayapak Wintachai; Supayang P Voravuthikunchai; Nicholas R Thomson; Peter W Taylor
Journal:  Front Cell Infect Microbiol       Date:  2021-06-18       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.